2677 (2677) Fair Value & Analysis

Healthcare · Market cap HK$1.9B

2 2677 2677 · HK

PriceHK$29.28

Fair ValueHK$41.04

Upside+40.2%

Quality46/100

Watch 2677 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$30.78 – HK$51.30

Fair value as of: Jul 2, 2026

From 22 valuation models · updated today

Share price +26.6% over the past month.

Price vs Fair Value (5 months)

5‑month range HK$21.66 – HK$67.90 · fair‑value band HK$30.78 – HK$51.30 · the HK$29.28 price screens below the HK$41.04 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2677 (2677) currently trades at HK$29.28, while our model-based Fair Value estimate is HK$41.04 — implying the stock looks roughly 40.2% undervalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 2677 generated revenue of HK$1.1B at a net margin of 12.7%. The stock trades on a trailing P/E of 12.1. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.1B

Net margin 12.7%

Free cash flow HK$146M FY2025

P/E ratio 12.1

Operating margin 2.7%

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2025 · reported fiscal years

2677 reported revenue of HK$1.1B in FY2025 versus HK$473M in FY2022, a compound +31.0%/yr. Reported net income was HK$135M in FY2025.

Revenue +31.0%/yr

FY22 HK$473M

FY23 HK$690M

FY24 HK$959M

FY25 HK$1.1B

Net income

FY22 −HK$215M

FY23 −HK$351M

FY24 HK$83.8M

FY25 HK$135M

Is 2677 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$95.75	R$123.65	+29%
Fresenius SE FSNUY	$11.30	$8.61	-24%
5225 5225	8.71 MYR	4.87 MYR	-44%
IHHHF IHHHF	$1.71	$1.17	-32%
Tenet Healthcare Corporation THC	$162.06	$282.55	+74%
Rede D'Or São Luiz S.A RDOR3	R$32.76	R$30.33	-7%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2677 (2677) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$41.04 versus a price of HK$29.28 — about +40% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2677?

Our model-based fair value for 2677 is HK$41.04 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$29.28.

What is the quality score of 2677?

2677 has a Quality Score of 46/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2677 (2677)?

2677 reported trailing-twelve-month revenue of about HK$1.1B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2677?

The net profit margin of 2677 is about 12.7%, meaning it keeps roughly 12.7% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.